Diagenode

ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.


Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG

ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.

Tags
IP-Star
Antibody

Share this article

Published
September, 2012

Source

Products used in this publication

  • ChIP-seq Grade
    C15310197
    AML1-ETO Antibody
  • ChIP-seq Grade
    C15310002
    CBFb Antibody
  • ChIP-seq Grade
    C15310001
    ETO Antibody
  • ChIP-seq Grade
    C15410005
    H3K9/14ac Antibody
  • ChIP-seq Grade
    C15200002
    TBP Antibody

Events

 See all events

 


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy